At this time of the year, the world divides into two groups: those with runny or blocked noses; watery and scratchy eyes; frequent sneezing; itchy nose, mouth, throat and ears; drippy noses and exhaustion and those lucky buggers that do not suffer the annual blight that is hay fever.
“Only” one in five of us actually has it, but it appears anecdotally to strike ever more people every spring.
If you are not stricken, you are truly blessed, because it is the most debilitating ailment that nobody at all wants to hear about, let alone make allowances for.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.